Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
69.32
+0.65 (0.95%)
Jul 22, 2026, 4:00 PM EDT - Market closed
Nektar Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 55.63 | 55.23 | 98.43 | 90.12 | 92.06 | 101.91 | |
Revenue Growth (YoY) | -36.24% | -43.89% | 9.21% | -2.10% | -9.67% | -33.36% |
Cost of Revenue | - | - | 30.69 | 33.77 | 21.64 | 24.9 |
Gross Profit | 55.63 | 55.23 | 67.74 | 56.35 | 70.42 | 77.01 |
Selling, General & Admin | 57.77 | 68.67 | 76.75 | 77.42 | 92.33 | 122.84 |
Research & Development | 122.53 | 117.33 | 120.91 | 114.16 | 218.32 | 400.27 |
Other Operating Expenses | 9.96 | 9.33 | 56.06 | 128.46 | 135.93 | - |
Total Operating Expenses | 190.25 | 195.33 | 253.72 | 320.04 | 446.59 | 523.11 |
Operating Income | -134.62 | -140.1 | -105.2 | -263.68 | -376.17 | -446.1 |
Interest Income | 11.81 | 10.44 | 14.5 | 19.01 | 6.78 | 2.73 |
Interest Expense | -29.15 | -26.18 | -28.11 | -25.33 | -28.91 | -47.31 |
Other Non-Operating Income (Expense) | -6.26 | -8.37 | -0.39 | -6.25 | 33.31 | -32.6 |
Total Non-Operating Income (Expense) | -17.59 | -15.39 | -14 | -12.57 | 11.18 | -77.18 |
Pretax Income | -152.21 | -155.49 | -119.2 | -276.26 | -364.98 | -523.28 |
Provision for Income Taxes | -0.13 | -0.14 | -0.24 | -0.2 | 3.22 | 0.56 |
Net Income | -152.08 | -155.35 | -118.96 | -276.06 | -368.2 | -523.84 |
Net Income to Common | -158.1 | -164.08 | -118.96 | -276.06 | -368.2 | -523.84 |
Shares Outstanding (Basic) | 20 | 17 | 14 | 13 | 12 | 12 |
Shares Outstanding (Diluted) | 20 | 17 | 14 | 13 | 12 | 12 |
Shares Change (YoY) | 39.46% | 23.05% | 8.24% | 1.53% | 2.10% | 2.64% |
EPS (Basic) | -8.42 | -9.73 | -8.68 | -21.75 | -29.55 | -42.90 |
EPS (Diluted) | -8.42 | -9.73 | -8.68 | -21.75 | -29.55 | -42.90 |
Free Cash Flow | -203.94 | -208.68 | -177.18 | -193.47 | -309.68 | -427.65 |
Free Cash Flow Per Share | -10.45 | -12.37 | -12.92 | -15.27 | -24.82 | -35.00 |
Gross Margin | 100.00% | 100.00% | 68.82% | 62.53% | 76.50% | 75.57% |
Operating Margin | -241.98% | -253.66% | -106.88% | -292.59% | -408.63% | -437.76% |
Profit Margin | -273.37% | -281.27% | -120.86% | -306.31% | -399.98% | -514.03% |
FCF Margin | -366.59% | -377.83% | -180.01% | -214.68% | -336.41% | -419.65% |
EBITDA | -133.87 | -139.08 | -100.81 | -255.87 | -363.14 | -431.96 |
EBITDA Margin | -240.63% | -251.80% | -102.42% | -283.91% | -394.48% | -423.87% |
EBIT | -134.62 | -140.1 | -105.2 | -263.68 | -376.17 | -446.1 |
EBIT Margin | -241.98% | -253.66% | -106.88% | -292.59% | -408.63% | -437.76% |
Effective Tax Rate | 0.08% | 0.09% | 0.20% | 0.07% | -0.88% | -0.11% |